Autobio Diagnostics Co., Ltd (SHA: 603658), a prominent player in China’s in vitro diagnostic market, has announced a strategic partnership with Japan’s Medical & Biological Laboratories (MBL). This collaboration will focus on advancing technologies in the microbial mass spectrometer field, although specific financial details of the agreement have not been disclosed.
MBL specializes in the research, development, manufacturing, and sales of clinical diagnostic and research reagents, encompassing areas such as immunology, molecular biology, and epigenomics. The company holds a commanding market share of over 80% in the autoimmune disease diagnostics sector in Japan, positioning it as a key player in the industry. This partnership is expected to enhance both companies’ capabilities in developing innovative diagnostic solutions. – Flcube.com
